Irradiation and Various Cytotoxic Drugs Enhance Tyrosine Phosphorylation and β1-Integrin Clustering in Human A549 Lung Cancer Cells in a Substratum-Dependent Manner in Vitro

Strahlentherapie und Onkologie

Volumn 180, Issue 3, 2004, Pages 157-164

  Cordes, Nils ^a,c   Beinke, Christina ^a   Plasswilm, Ludwig ^b   Van Beuningen, Dirk ^a  

^a Institute of Radiobiology   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Bundeswehr Institute of Radiobiology   (Germany)

Author keywords

1 integrin; Clustering; Drugs; Extracellular matrix; Ionizing radiation

Indexed keywords

ANTIBODY; BETA1 INTEGRIN; CISPLATIN; CYTOTOXIC AGENT; FIBRONECTIN; MITOMYCIN; PACLITAXEL; POLYSTYRENE; SCLEROPROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMING CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE; IRRADIATION; LUNG CANCER; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CELL ADHESION; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; COLONY-FORMING UNITS ASSAY; EXTRACELLULAR MATRIX PROTEINS; FIBRONECTINS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INTEGRIN BETA CHAINS; LUNG NEOPLASMS; MICROSCOPY, CONFOCAL; MITOMYCIN; PACLITAXEL; PHOSPHORYLATION; POLYSTYRENES; RADIATION DOSAGE; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION; TYROSINE;

EID: 1542319906     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-004-1144-2     Document Type: Article

References (48)

1. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-804.
2. Budach W, Paulsen F, Welz S, et al. Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma. Br J Cancer 2002;86:470-6.
3. Burridge K, Chrzanowska-Wodnicka M. Focal adhesions, contractility, and signaling. Annu Rev Cell Dev Biol 1996;12:463-519.
4. Burridge K, Fath K, Kelly T, et al. Focal adhesions: transmembrane junctions between the extracellular matrix and the cytoskeleton. Annu Rev Cell Biol 1988;4:487-525.
5. Bushman WA, Wilson LK, Luttrell DK, et al. Overexpression of c-src enhances beta-adrenergic-induced cAMP accumulation. Proc Natl Acad Sci U S A 1990;87:7462-6.
6. Chen WT, Hasegawa E, Hasegawa T, et al. Development of cell surface linkage complexes in cultured fibroblasts. J Cell Biol 1985;100:1103-14.
7. Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science 1995;268:233-9.
8. 1-integrin in lung tumour cell lines in vitro. Int J Radiat Biol 2002;78:347-57.
9. Cordes N, Blaese MA, Plasswilm L, et al. Fibronectin and laminin increase resistance to ionising radiation and the cytotoxic drug Ukrain® in human tumour and normal cells in vitro. Int J Radiat Biol 2003;79:709-20.
10. Cordes N, Meineke V. Cell adhesion-mediated radioresistance (CAMRR): extracellular matrix-dependent improvement of cell survival in human tumor and normal cells in vitro. Strahlenther Onkol 2003;179:337-44.
11. Cordes N, Plasswilm L, Sauer R. Interaction of paclitaxel (Taxol) and irradiation. In-vitro differences between tumor and fibroblastic cells. Strahlenther Onkol 1999;175:175-81.
12. Cordes N, van Beuningen D. Cell adhesion to the extracellular matrix protein fibronectin modulates radiation-dependent G2 phase arrest involving integrin-linked kinase (ILK) and glycogen synthase kinase-3β (GSK-3β) in vitro. Br J Cancer 2003;88:1470-9.
13. Cummings BJ, Keane TJ, O'Sullivan B, et al. Mitomycin in anal canal carcinoma. Oncology 1993;50:Suppl 1:63-9.
14. Damiano JS, Cress AE, Hazlehurst LA, et al. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658-67.
15. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the intrinsic death machinery. Cell 1997;91:231-41.
16. Diehl JA, Cheng M, Roussel MF, et al. Gylcogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499-511.
17. Dobrowsky W, Naude J. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. Radiother Oncol 2000;57:119-24.
18. Fietkau R. Concomitant radiochemotherapy of advanced non-small-cell lung cancer. Lung Cancer 2001;33:Suppl 1:65-76.
19. Fietkau R, Iro H, Grabenbauer GG, et al. Simultaneous radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in advanced head and neck tumors. Strahlenther Onkol 1991;167:693-700.
20. Fuks Z, Vlodavsky I, Andreeff M, et al. Effects of extracellular matrix on the response of endothelial cells to radiation in vitro. Eur J Cancer 1992;28a:725-31.
21. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999;285:1028-32.
22. Grabenbauer GG, Panzer M, Hultenschmidt B, et al. The prognostic factors following the simultaneous radiochemotherapy of anal canal carcinoma in a multicenter series of 139 patients. Strahlenther Onkol 1994;170:391-9.
23. 1-integrin-linked protein kinase. Nature 1996;379:91-6.
24. 1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000;19:4319-27.
25. Hoeflich KP, Luo J, Rubie EA, et al. Requirement for glycogen synthase kinase-3beta in cell survival and NK-κB activation. Nature 2000;406:86-90.
26. Howe A, Aplin AE, Alahari SK, et al. Integrin signaling and cell growth. Curr Opin Cell Biol 1998;10:220-31.
27. Hughes PE, Renshaw MW, Pfaff M, et al. Suppression of integrin activation: a novel function of a rRas/Raf-initiated MAP kinase pathway. Cell 1997;88:521-30.
28. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-87.
29. Kanner SB, Reynolds AB, Vines RR, et al. Monoclonal antibodies to individual tyrosine-phosphorylated protein substrates of oncogene-encoded tyrosine kinases. Proc Natl Acad Sci U S A 1990;87:3328-32.
30. Khwaja A, Rodriguez-Viciana P, Wennström S, et al. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J 1997;16:2783-93.
31. Liebmann JE, Cook JA, Lipschultz C. Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines. Br J Cancer 1993;68:1104-9.
32. Matten WT, Aubry M, West J, et al. Tubulin is phosphorylated at tyrosine by pp60c-src in nerve growth cone membranes. J Cell Biol 1990;111:1959-70.
33. Meineke V, Gilbertz KP, Schilperoort K, et al. Ionizing radiation modulates cell surface integrin expression and adhesion of COLO-320 cells to collagen and fibronectin in vitro. Strahlenther Onkol 2002;178:709-14.
34. Meredith JE Jr, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993;4:953-61.
35. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-43.
36. Mucke R, Ziegler PG, Libera T, et al. The multimodality therapy of advanced inoperable esophageal carcinoma. A retrospective analysis. Strahlenther Onkol 2000;176:350-5.
37. Plasswilm L, Kirschner M, Sauer R. Concurrent Taxol and split-course accelerated radiotherapy for advanced head and neck cancer. Strahlenther Onkol 1996;172:573-9.
38. Rose RW, O'Hara MO, Williamson SK, et al. The role of laminin-1 in the modulation of radiation damage in endothelial cells and differentiation. Radiat Res 1999;152:14-28.
39. Rowinsky EK, Donehower RC. Drug therapy: paclitaxel (Taxol). N Engl J Med 1995;332:1004-14.
40. Schaller MD. Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta 2001:1540:1-21.
41. Schwartz MA, Ginsberg MH. Networks and crosstalk: integrin signalling spreads. Nature Cell Biol 2002;4:E65-8.
42. Sethi T, Rintoul RC, Moore SM, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999;5:662-8.
43. Strauss HG, Kuhnt T, Laban C, et al. Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study. Strahlenther Onkol 2002;178:378-85.
44. Stuschke M, Budach V, Dinges S, et al. Accelerated hyperfractionated radiotherapy combined with simultaneous chemotherapy in locally advanced pharyngeal and oral carcinomas. Strahlenther Onkol 1994;170:689-99.
45. Troussard AA, Tan C, Yoganathan TN, et al. Cell-extracellular matrix interactions stimulate the AP-1 transcription factor in an integrin-linked kinase- and glycogen synthase kinase 3-dependent manner. Mol Cell Biol 1999;19:7420-7.
46. Vokes EE, Choy H, Gandara D, et al. Adjuvant and neoadjuvant treatments for NSCLC. Lung Cancer 2002;38:Suppl:29-35.
47. Watt FM. Role of integrins in regulating epidermal adhesion, growth and differentiation. EMBO J 2002;21:19-26.
48. Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem 1988;57:443-78.